Halozyme Therapeutics revenue and financials
$109.72Change from previous close: +1.30%Absolute change: +$1.41
In the fiscal year ended December 2025, Halozyme Therapeutics reported revenue of $1.4B (+37.55% year over year). Net income was $316.89M, a net margin of 22.7%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +37.55%
- 2025 vs 2024
- Net income growth
- −28.64%
- 2025 vs 2024
- Net margin
- 22.7%
- 2024: 43.7%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 652 | 479 | 389 | 240 | 299 | 55.5 | -85.4 | -49.5 | 134 | -50.4 |
| Depreciation and amortization | 11.4 | 10.3 | 11.1 | 6.5 | 3.0 | 3.3 | 4.1 | 2.4 | 2.2 | 2.4 |
| Capital expenditure | -7.0 | -10.7 | -15.3 | -4.8 | -1.5 | -2.5 | -4.0 | -4.7 | -1.4 | -3.1 |
| Investing cash flow | -546 | -263 | -96.9 | -487 | -406 | — | — | — | — | — |
| Financing cash flow | -85.2 | -219 | -408 | 362 | 77.9 | — | — | — | — | — |
| Share repurchases | -342 | -250 | -402 | -200 | -350 | -150 | -200 | 0.0 | 0.0 | — |
| Debt issued | 1,470 | 0.0 | 0.0 | 1,072 | 785 | — | — | — | — | — |
| Debt repaid | -845 | 0.0 | -13.5 | -447 | -369 | — | — | — | — | — |
| Net change in cash | 20.6 | -2.5 | -116 | 115 | -29.0 | — | — | — | — | — |
| Free cash flow | 645 | 468 | 373 | 235 | 298 | — | — | — | — | — |
| Levered free cash flow | 185 | 402 | 276 | 146 | 198 | — | — | — | — | — |